465 related articles for article (PubMed ID: 28108741)
1. Metabolism, toxicity and anticancer activities of arsenic compounds.
Khairul I; Wang QQ; Jiang YH; Wang C; Naranmandura H
Oncotarget; 2017 Apr; 8(14):23905-23926. PubMed ID: 28108741
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of arsenic and toxicological implication of arsenic metabolites.
Hirano S
Arch Toxicol; 2020 Aug; 94(8):2587-2601. PubMed ID: 32435915
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
4. The cellular metabolism and systemic toxicity of arsenic.
Thomas DJ; Styblo M; Lin S
Toxicol Appl Pharmacol; 2001 Oct; 176(2):127-44. PubMed ID: 11601889
[TBL] [Abstract][Full Text] [Related]
5. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
6. Double-edged effects of arsenic compounds: anticancer and carcinogenic effects.
Rehman K; Naranmandura H
Curr Drug Metab; 2013 Dec; 14(10):1029-41. PubMed ID: 24164099
[TBL] [Abstract][Full Text] [Related]
7. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
8. Role of arsenic (+3 oxidation state) methyltransferase in arsenic mediated APL treatment: an in vitro investigation.
Maimaitiyiming Y; Wang C; Xu S; Islam K; Chen YJ; Yang C; Wang QQ; Naranmandura H
Metallomics; 2018 Jun; 10(6):828-837. PubMed ID: 29774349
[TBL] [Abstract][Full Text] [Related]
9. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Chen B; Cao F; Yuan C; Lu X; Shen S; Zhou J; Le XC
Anal Bioanal Chem; 2013 Feb; 405(6):1903-11. PubMed ID: 23318765
[TBL] [Abstract][Full Text] [Related]
10. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
11. Methylated arsenicals: the implications of metabolism and carcinogenicity studies in rodents to human risk assessment.
Cohen SM; Arnold LL; Eldan M; Lewis AS; Beck BD
Crit Rev Toxicol; 2006 Feb; 36(2):99-133. PubMed ID: 16736939
[TBL] [Abstract][Full Text] [Related]
12. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of arsenic and its toxicological relevance.
Watanabe T; Hirano S
Arch Toxicol; 2013 Jun; 87(6):969-79. PubMed ID: 22811022
[TBL] [Abstract][Full Text] [Related]
14. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update.
Stýblo M; Drobná Z; Jaspers I; Lin S; Thomas DJ
Environ Health Perspect; 2002 Oct; 110 Suppl 5(Suppl 5):767-71. PubMed ID: 12426129
[TBL] [Abstract][Full Text] [Related]
15. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells.
Chen GQ; Zhou L; Styblo M; Walton F; Jing Y; Weinberg R; Chen Z; Waxman S
Cancer Res; 2003 Apr; 63(8):1853-9. PubMed ID: 12702573
[TBL] [Abstract][Full Text] [Related]
16. Analysis of arsenic metabolites in HepG2 and AS3MT-transfected cells.
Watanabe T; Ohta Y; Mizumura A; Kobayashi Y; Hirano S
Arch Toxicol; 2011 Jun; 85(6):577-88. PubMed ID: 21537954
[TBL] [Abstract][Full Text] [Related]
17. Monomethylarsonous acid binds to Cys-104α and Cys-112β of hemoglobin in acute promyelocytic leukemia patients treated with arsenic trioxide.
Gao C; Lin L; Li J; Wu M; Lv J; Tian S; Hai X
Toxicol Lett; 2023 May; 380():31-39. PubMed ID: 37024065
[TBL] [Abstract][Full Text] [Related]
18. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide.
Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J
Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As
Liu WS; Wang XY; Lu J; Zhang YM; Ye XM; Li JM; Zhao QL; Wu ZQ; Zhou J; Hai X
Arch Toxicol; 2020 Apr; 94(4):1203-1213. PubMed ID: 32112223
[TBL] [Abstract][Full Text] [Related]
20. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells.
Styblo M; Del Razo LM; Vega L; Germolec DR; LeCluyse EL; Hamilton GA; Reed W; Wang C; Cullen WR; Thomas DJ
Arch Toxicol; 2000 Aug; 74(6):289-99. PubMed ID: 11005674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
